These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 26073023

  • 1. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, Ishikawa H, Mizuno M, Sada T.
    Eur J Pharmacol; 2015 Aug 15; 761():226-34. PubMed ID: 26073023
    [Abstract] [Full Text] [Related]

  • 2. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
    Arai K, Tsuruoka H, Homma T.
    Eur J Pharmacol; 2015 Dec 15; 769():266-73. PubMed ID: 26607463
    [Abstract] [Full Text] [Related]

  • 3. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
    Nariai T, Fujita K, Mori M, Katayama S, Hori S, Matsui K.
    J Pharmacol Sci; 2011 Dec 15; 115(3):346-53. PubMed ID: 21358118
    [Abstract] [Full Text] [Related]

  • 4. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
    Arai K, Morikawa Y, Ubukata N, Tsuruoka H, Homma T.
    J Pharmacol Exp Ther; 2016 Sep 15; 358(3):548-57. PubMed ID: 27384074
    [Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
    Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, Geschwindner S, Aagaard A, Björnson Granqvist A, Jaisser F, Huang Y, Granberg KL, Jansson-Löfmark R, Hartleib-Geschwindner J.
    PLoS One; 2018 Sep 15; 13(2):e0193380. PubMed ID: 29474466
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Sep 15; 5(5):354-63. PubMed ID: 14503934
    [Abstract] [Full Text] [Related]

  • 9. Eplerenone: a new selective aldosterone receptor antagonist.
    Weinberger MH.
    Drugs Today (Barc); 2004 Jun 15; 40(6):481-5. PubMed ID: 15349128
    [Abstract] [Full Text] [Related]

  • 10. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
    Rahmouni K, Sibug RM, De Kloet ER, Barthelmebs M, Grima M, Imbs JL, De Jong W.
    Eur J Pharmacol; 2002 Feb 02; 436(3):207-16. PubMed ID: 11858800
    [Abstract] [Full Text] [Related]

  • 11. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
    Rogerson FM, Yao Y, Smith BJ, Fuller PJ.
    Clin Exp Pharmacol Physiol; 2004 Oct 02; 31(10):704-9. PubMed ID: 15554912
    [Abstract] [Full Text] [Related]

  • 12. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt.
    Liu S, Xie Z, Daugherty A, Cassis LA, Pearson KJ, Gong MC, Guo Z.
    Arterioscler Thromb Vasc Biol; 2013 Jul 02; 33(7):1568-79. PubMed ID: 23661677
    [Abstract] [Full Text] [Related]

  • 13. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, Fagart J.
    J Biol Chem; 2015 Sep 04; 290(36):21876-89. PubMed ID: 26203193
    [Abstract] [Full Text] [Related]

  • 14. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C.
    Int J Cardiol; 2015 Dec 01; 200():25-9. PubMed ID: 26404748
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
    Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L.
    Hypertension; 2014 Apr 01; 63(4):797-803. PubMed ID: 24420551
    [Abstract] [Full Text] [Related]

  • 17. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X, Li S, McMahon EG, Lala DS, Rudolph AE.
    Mini Rev Med Chem; 2005 Aug 01; 5(8):709-18. PubMed ID: 16101407
    [Abstract] [Full Text] [Related]

  • 18. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
    Mihailidou AS, Mardini M, Funder JW, Raison M.
    Hypertension; 2002 Aug 01; 40(2):124-9. PubMed ID: 12154101
    [Abstract] [Full Text] [Related]

  • 19. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
    Takeda Y.
    Hypertens Res; 2004 Nov 01; 27(11):781-9. PubMed ID: 15824460
    [Abstract] [Full Text] [Related]

  • 20. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats.
    Rafiq K, Nakano D, Ihara G, Hitomi H, Fujisawa Y, Ohashi N, Kobori H, Nagai Y, Kiyomoto H, Kohno M, Nishiyama A.
    J Hypertens; 2011 Feb 01; 29(2):290-8. PubMed ID: 21243738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.